Piper Jaffray Raises Price Target as Amedisys (AMED) Raises Acquisition Pipeline
Tweet Send to a Friend
Piper Jaffray reiterated a Neutral rating on Amedisys (NASDAQ: AMED), and raised the price target to $45.00 (from $42.00), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
